Tags : Mitsubishi Tanabe Pharma

Top 20 Immunology Companies Based 2019 Immunology Segment Revenue

Immunology is an important branch of science which deals with the study of the immune system. The immune system is a highly regulated and balanced system and when the balance is disturbed, the disease can result. A lot of this work has importance in the development of new therapies and treatments that can handle or […]Read More

PharmaShots’ Most Read News of 2019

The year 2019 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements and gaining approvals. Our team has compiled a list of 20 most read life sciences news on PharmaShots in 2019. 1. Celltrion Signed an Exclusive Co-Marketing Agreement with Juno in Australia Juno provided sales […]Read More

Top 20 Immunology Companies Based on 2018 Immunology Segment Revenue

The increasing cases of autoimmune disorders such as rheumatoid arthritis are driving the growth of immunology products in the global market. Multiple companies have been focusing on Oncology, Hematology and multiple diseases but due to a drastic increase in the immune disorders, Immunology segment has been widely spared across the globe. In the top 20 […]Read More

Salix (Bausch Health) Signs an Exclusive License Agreement with Mitsubishi

Shots: MTPC to receive upfront, development & regulatory milestones and royalties on sales. Bausch Health to get exclusive WW rights to develop & commercialize MT-1303 (Ex-Japan & few other countries in Asia) in all fields (Ex. neurology, rheumatology and certain rare dermatology diseases) Bausch plans to initiate the development of MTPC’s MT-1303 (amiselimod) in ulcerative […]Read More

Mitsubishi Tanabe Pharma (MTPA) Collaborates with Massachusetts General Hospital (MGH)

Shots: Mitsubishi Tanabe Pharma (MTPA) enters into a collaboration with Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI) to conduct ALS biomarker study for identification of biomarkers in patients with amyotrophic lateral sclerosis (ALS) The ALS biomarker study will evaluate 4 biomarkers enrolling 200 patients receiving Radicava (edaravone) for 24wks. across 40 sites and […]Read More